Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
about
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitusGliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular diseaseImpact of hypoglycemic agents on myocardial ischemic preconditioningDipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in ratsLinagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesityIncretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitusDipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.Clinical utility of fixed combinations of sitagliptin-metformin in treatment of type 2 diabetes.Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome.Retrospective analysis on the efficacy, safety and treatment failure group of sitagliptin for mean 10-month durationExtracellular proteases as targets for drug developmentFour-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC StudyEfficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injuryInhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiationDiabetes mellitus: new challenges and innovative therapies.Sitagliptin downregulates retinol-binding protein 4 and upregulates glucose transporter type 4 expression in a type 2 diabetes mellitus rat model.Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden.New combination treatments in the management of diabetes: focus on sitagliptin-metformin.Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats.PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment.A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment.Role of postprandial hyperglycemia in cardiovascular disease.Personalized pharmacotherapy for Type 2 diabetes mellitus.Effects of a novel curcumin derivative on insulin synthesis and secretion in streptozotocin-treated rat pancreatic islets in vitro.Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.Incretin agents in type 2 diabetes.Add-on therapies to metformin for type 2 diabetes.Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin.Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.Dipeptidyl peptidase-IV and related molecules: markers of malignancy?Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.Discontinued drugs in 2008: endocrine and metabolic.Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?Teneligliptin Decreases Uric Acid Levels by Reducing Xanthine Dehydrogenase Expression in White Adipose Tissue of Male Wistar Rats.DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety.The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes.
P2860
Q24243196-5D41D0FC-F58D-40FB-9A7F-FCE34F398832Q26741067-CC0A871C-B3FD-4EF1-9C7D-50511A9AA56DQ27014018-A6F3107B-E822-4C3D-8E57-1C1E5868ECFEQ28286911-517EFA68-F266-4477-9B33-F7C8A00F4C86Q28728101-E80BB757-A173-4ED3-BE6B-A7AB9C9EDCADQ34374350-1C2C4D16-5C74-4E8E-ADB5-F1843B7B23BBQ34597496-6D027010-FF89-4A02-AEDB-7599973536A1Q34620565-6FDF04DA-C159-4F83-A283-2669A0BA9365Q34718822-B660E4BB-082A-4FC5-BA5C-47916D51ECAEQ35063234-D05C6531-5B07-4364-AA2C-82434066D331Q35110343-A267A647-7AD8-483B-BCC6-706A91CAE787Q35116202-0DFB92B4-1D4B-42FF-8CAB-75ED56362298Q35661969-114B1576-7240-4060-B0CA-CEDAD9DB58FEQ35849028-2876C2DC-1BDB-4FE2-978B-A325C9D43791Q35916947-CAC675BA-0CD7-41C5-AAE4-C77CD28130F9Q36117595-92B3ABE0-25F9-43E5-91BE-1678DE0F79C9Q36411670-2D1FD2B9-87A7-4DE4-A3F6-3F1962A68CF8Q36812821-10F88238-8D0E-494B-865E-8ED403E2557AQ36989711-FC02D0F4-EED5-448D-A104-E0EC4C239771Q37004040-9490F559-4B09-408B-88BE-3D1EFC6AC2B2Q37033531-61138F1D-4D50-4B40-B1ED-5FCF49D9DAEAQ37101005-299E19E9-B948-4F3B-AF42-BA5C35F45A95Q37164446-2097A526-749A-4655-B351-3AC64F4A3071Q37197094-BF5B2B86-6A99-4493-BE0B-D0A82B530870Q37365702-8AC5CA92-66AC-4C5B-9010-F000086D42D3Q37497514-65A0ABDE-B36A-490F-9ACA-812A979E34B3Q37598881-EFF208E8-E543-4777-9C04-27D0EFD5F2E4Q37772709-B57276F6-AC35-4E3F-A0FC-66510686A848Q37818234-E2D60101-934C-4D55-A62C-3EBC9B5EE0C0Q37857686-CF551620-F803-474A-A859-275196C9C04CQ37941683-6E888E63-8362-4940-AC99-20837731AA9DQ38089765-06CEED81-07EB-4B35-93E7-24B6380FCB0CQ38177173-AB777505-F13A-4EDC-8732-65A2739FBB39Q38238949-12BA8899-6D3E-44FA-9212-FB7E823D2A8AQ38449224-9D77DCC2-264C-4B00-A503-DF378AFE5359Q39157526-A33811D9-1679-44E3-AC87-EA8CD678B5A8Q41070039-C72AA534-E212-474E-AE82-F677C0BF7C4DQ41867493-5357211C-13C5-4765-93A8-B310F4FB6BDEQ41883921-993EDAFB-081C-409A-90AF-8258C891B44FQ42876331-F13B98D0-F685-432F-990B-3E67F350360D
P2860
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
@ast
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
@en
type
label
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
@ast
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
@en
prefLabel
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
@ast
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
@en
P356
P1433
P1476
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
@en
P2093
P304
P356
10.2337/DC07-0233
P407
P577
2007-03-02T00:00:00Z